Connect Biopharma Completes Enrollment in Phase 2 Asthma Trial, Aims for September Data Readout
Event summary
- Connect Biopharma completed enrollment in its Phase 2 Seabreeze STAT Asthma study evaluating rademikibart for acute asthma exacerbations.
- The study enrolled 160 participants globally with type 2 inflammation and eosinophil counts ≥300 cells/μL.
- Topline data from the study is expected in early September 2026, with plans to meet with the FDA later this year to align on a Phase 3 program.
- The company also anticipates completing enrollment in its Phase 2 Seabreeze STAT COPD study this month.
The big picture
Connect Biopharma's progress in its Phase 2 trials for rademikibart highlights the growing focus on biologic therapies for acute exacerbations in asthma and COPD. The company's strategic positioning in the inflammatory disease space, coupled with its partnership with Simcere Pharmaceutical in Greater China, underscores the potential for regional expansion and significant market opportunities. The upcoming data readouts will be critical in assessing the competitive landscape and the therapeutic potential of rademikibart.
What we're watching
- Regulatory Alignment
- Whether Connect Biopharma can secure FDA alignment on a Phase 3 program for rademikibart later this year, accelerating its path to market.
- Clinical Efficacy
- The pace at which topline data from the Seabreeze STAT Asthma study demonstrates differentiated therapeutic profile for rademikibart.
- Financial Runway
- How Connect Biopharma's strong balance sheet with cash runway into 2H 2027 supports its operational and development plans.
Related topics